BMS and Sanofi-Aventis Prevail over Apotex in Plavix Patent Litigation

June 20, 2007

Our “blogfather” over at the Orange Book Blog already has a preliminary post up about the recent victory in the district court by Bristol-Myers Squibb and Sanofi-Aventis over Apotex relating to the enforceability and validity of the patent on the active ingredient in Plavix.  Long story short:  The patent is valid and Apotex is enjoined from further infringing the patent.

Aaron Barkoff, the blogmaster at OBB, always does a nice job summarizing the patent cases for those of us with liberal arts degrees whose eyes glaze over at the intricacies of patent law.  We look forward to his forthcoming detailed post on the topic.

Categories: Hatch-Waxman